Gynaecomastia due to liver cirrhosis is a well-recognised complication of advanced liver disease, affecting a significant proportion of men with hepatic impairment. The damaged liver loses its ability to metabolise sex hormones effectively, leading to a relative excess of oestrogen over free testosterone — a hormonal imbalance that directly stimulates breast tissue growth. This article explains why cirrhosis causes gynaecomastia, how it is diagnosed and managed within the NHS, which medications may worsen the condition, and when men should seek urgent medical attention.

Why Liver Cirrhosis Can Cause Gynaecomastia

Cirrhosis impairs the liver's ability to clear oestrogens and alters SHBG production, creating a relative oestrogen excess over free testosterone that directly stimulates benign breast tissue growth in men.

Gynaecomastia — the benign enlargement of glandular breast tissue in men — is a well-recognised complication of liver cirrhosis. It is common in men with advanced liver disease, though reported prevalence varies widely across studies depending on the severity of cirrhosis and the population studied. Understanding why this happens requires an appreciation of the liver's central role in hormone metabolism.

The liver is responsible for metabolising and clearing sex hormones, including oestrogens and androgens, from the bloodstream. In cirrhosis, widespread hepatocyte damage and fibrosis impair this metabolic function significantly. As a result, oestrogens — particularly oestradiol and oestrone — accumulate in the circulation. At the same time, the liver's capacity to produce sex hormone-binding globulin (SHBG) is altered; SHBG typically increases in cirrhosis, which reduces the amount of free (biologically active) testosterone available, further disrupting the balance between androgens and oestrogens.

This relative excess of oestrogen compared to free testosterone acts directly on breast tissue, stimulating the proliferation of ductal and stromal elements. The condition is not merely cosmetic; it can cause discomfort and psychological distress. Its presence in a man with known or suspected liver disease should prompt thorough clinical evaluation in the context of overall liver status, rather than reassurance alone.

How Cirrhosis Disrupts Hormone Balance in Men

Cirrhosis disrupts hormone balance through increased peripheral aromatisation, hypogonadism affecting the HPG axis, elevated SHBG, and direct testicular toxicity from alcohol, often compounded by anti-androgenic medications such as spironolactone.

The hormonal disruption seen in cirrhosis is multifactorial and involves several interconnected pathways. One key mechanism is the increased peripheral conversion of androgens to oestrogens — a process known as aromatisation — which occurs predominantly in adipose tissue and the liver itself. In cirrhosis, this conversion is amplified, partly due to elevated levels of androstenedione, a precursor hormone that is inadequately cleared by the damaged liver.

Additionally, cirrhosis is associated with both primary and secondary hypogonadism, and the pattern varies between individuals. In secondary (central) hypogonadism, disruption to the hypothalamic-pituitary-gonadal (HPG) axis leads to reduced secretion of luteinising hormone (LH) and follicle-stimulating hormone (FSH), suppressing testicular testosterone production. In primary testicular failure, LH and FSH are typically elevated. Measuring these hormones helps to localise the cause. SHBG is typically increased in cirrhosis, further reducing free testosterone regardless of the pattern of hypogonadism.

Alcohol-related cirrhosis introduces further complexity. Alcohol itself has direct toxic effects on the testes, impairing testosterone synthesis independently of liver damage. It also increases adrenal androgen secretion and enhances peripheral aromatisation.

Certain medications commonly used in cirrhosis management can independently cause or worsen gynaecomastia. Spironolactone, a potassium-sparing diuretic used to treat ascites, has well-established anti-androgenic properties and is one of the most common drug-related causes in this population (see MHRA/EMC SmPC for spironolactone). Other drugs associated with gynaecomastia that men with cirrhosis may be prescribed include:

• Cimetidine (an H2-receptor antagonist with anti-androgenic effects — note: proton pump inhibitors are not an established cause)

• Ketoconazole (antifungal with effects on androgen synthesis)

• Digoxin (oestrogenic activity)

• Opioid analgesics (which can cause opioid-induced hypogonadism)

• Certain antipsychotics (e.g., risperidone, via hyperprolactinaemia)

• 5-alpha-reductase inhibitors such as finasteride or dutasteride

• Anti-androgens and certain antiretrovirals

• Anabolic steroids and cannabis

If you suspect a medicine is causing or worsening gynaecomastia, this can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk. The BNF provides a comprehensive list of drugs associated with gynaecomastia.

This polypharmacy context means that in men with cirrhosis, gynaecomastia is often the result of overlapping hormonal and pharmacological factors rather than a single cause.

Recognising the Symptoms and When to Seek Help

Gynaecomastia typically presents as a firm, rubbery subareolar disc with tenderness; men should seek urgent assessment if they notice a hard irregular lump, skin changes, nipple retraction, or axillary lymphadenopathy, as per NICE NG12.

Gynaecomastia typically presents as a palpable, rubbery or firm disc of tissue beneath the nipple-areolar complex, which may be unilateral or bilateral. Men with cirrhosis-related gynaecomastia often describe:

• Breast tenderness or sensitivity, particularly in the early, active phase

• Visible swelling or fullness beneath one or both nipples

• Nipple discharge in some cases, though this is less common

• Psychological distress, including embarrassment or anxiety about body image

It is important to distinguish true gynaecomastia from pseudogynaecomastia, which refers to fatty tissue deposition without glandular proliferation and is common in overweight men. True gynaecomastia involves firm, concentric glandular tissue and is clinically distinct on examination.

Men should seek prompt medical attention if they notice any of the following red flag features, which may warrant urgent assessment or referral via the suspected cancer pathway (in line with NICE guideline NG12):

• A hard, irregular, or rapidly enlarging lump — this may suggest breast carcinoma, which, although rare in men, must be excluded

• Unilateral breast swelling with skin changes, nipple retraction, or axillary lymphadenopathy

• Nipple discharge, especially if bloodstained — do not squeeze the nipple to check for discharge

• Sudden onset of breast swelling without an obvious cause

NICE NG12 recommends considering an urgent two-week-wait referral for men aged 50 and over with a unilateral, firm subareolar mass with or without nipple discharge, or for any man with suspicious features such as skin changes, nipple retraction, or axillary lymphadenopathy.

While gynaecomastia in the context of known cirrhosis is usually benign, any new or changing breast lump warrants clinical assessment. Men should contact their GP or hepatology team rather than assuming the change is simply related to their liver disease.

Diagnosis and Assessment on the NHS

Assessment includes clinical examination, liver function tests, and a hormonal profile covering testosterone, LH, FSH, oestradiol, SHBG, prolactin, beta-hCG, and thyroid function; breast ultrasound is the preferred first-line imaging modality in men.

Assessment of gynaecomastia in a man with cirrhosis begins with a thorough clinical history and physical examination. The clinician will assess the size, consistency, and symmetry of breast tissue, alongside a review of current medications, alcohol history, and the severity of underlying liver disease — often graded using the Child-Pugh, MELD, or UKELD scoring systems (UKELD is used in UK transplant listing).

Blood tests form the cornerstone of initial investigation and typically include:

• Liver function tests (LFTs) and clotting studies to assess hepatic synthetic function

• Serum testosterone, LH, FSH, oestradiol, and SHBG to characterise the hormonal profile and localise hypogonadism

• Prolactin — to exclude hyperprolactinaemia as a contributing cause

• Beta-hCG — to screen for testicular germ-cell tumours, which can independently cause gynaecomastia

• Thyroid function tests (TSH) — both hypothyroidism and hyperthyroidism are associated with gynaecomastia

Note: alpha-fetoprotein (AFP) is not a routine part of the gynaecomastia work-up; its use is reserved for hepatocellular carcinoma (HCC) surveillance in appropriate patients with cirrhosis.

A testicular examination should be performed in all men presenting with gynaecomastia, and testicular ultrasound should be considered if beta-hCG is elevated or a testicular mass is suspected, to exclude a germ-cell tumour.

For men referred to a symptomatic breast clinic, assessment follows the triple assessment approach: clinical history and examination, imaging, and needle sampling if indicated. Imaging in men with breast symptoms is guided by the Royal College of Radiologists (RCR) iRefer guidelines and Association of Breast Surgery (ABS) guidance; breast ultrasound is the preferred first-line imaging modality in men. Mammography may be used in selected cases. Referral to a two-week-wait breast clinic should be made if red flag features are present, in line with NICE NG12.

In men with established cirrhosis, the diagnosis of gynaecomastia is often clinical, and extensive investigation may not alter management. However, excluding reversible or treatable causes — particularly drug-induced gynaecomastia — remains an important step in the assessment process.

Managing Gynaecomastia in Patients with Cirrhosis

Management prioritises medication review — particularly switching from spironolactone to amiloride where appropriate — with off-label tamoxifen or raloxifene considered for symptomatic early-phase disease under specialist supervision.

Management of gynaecomastia in cirrhosis is guided by the underlying cause, symptom severity, and the overall clinical condition of the patient. The primary goal is to address the root cause of hormonal imbalance where possible, rather than treating the breast tissue change in isolation.

Medication review is an essential first step. If spironolactone is identified as a contributing factor, the clinical team may consider switching to an alternative diuretic such as amiloride, which has fewer anti-androgenic effects, in line with BSG/BASL guidance on ascites management. This decision must be balanced carefully against the risk of worsening ascites or electrolyte disturbance, and should only be made by the supervising hepatology or gastroenterology team.

For men in whom gynaecomastia is causing significant pain or psychological distress, pharmacological options may be considered. Medical treatment is most effective in the early, active (tender and proliferative) phase — typically within approximately six to twelve months of onset. Once fibrotic change is established, pharmacological benefit is limited. All pharmacological options below are used off-label for this indication and should only be initiated under specialist supervision, with close monitoring given the risks of hepatic impairment:

• Tamoxifen (an oestrogen receptor antagonist) has shown modest benefit in small studies for symptomatic gynaecomastia. Prescribers should consult the SmPC for cautions in hepatic impairment and venous thromboembolism (VTE) risk.

• Raloxifene is another selective oestrogen receptor modulator (SERM) with some supporting evidence. Similar cautions regarding hepatic impairment and VTE apply.

• Aromatase inhibitors such as anastrozole have been explored but generally show limited benefit for gynaecomastia and should be used with particular caution in the context of liver impairment; consult the SmPC before use.

Suspected adverse reactions to any of these medicines should be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Surgical intervention — specifically subcutaneous mastectomy — may be appropriate for men with longstanding, fibrotic gynaecomastia that has not responded to medical management and is causing significant distress. However, surgical risk is substantially elevated in patients with advanced cirrhosis due to coagulopathy and poor wound healing. Careful multidisciplinary assessment and perioperative risk optimisation are essential before proceeding.

Underlying liver disease management — including alcohol cessation, antiviral therapy for viral hepatitis, and nutritional support — remains the most important long-term strategy.

Outlook and Monitoring for Men with Liver Disease

Prognosis is linked to underlying liver disease trajectory; established fibrotic gynaecomastia is unlikely to resolve spontaneously, but hormonal profiles may partially normalise with successful liver disease treatment such as hepatitis C antivirals or alcohol abstinence.

The prognosis of gynaecomastia in men with cirrhosis is closely tied to the trajectory of the underlying liver disease. In early or compensated cirrhosis, hormonal disruption may be modest and gynaecomastia mild. As liver disease progresses to decompensated cirrhosis — characterised by ascites, variceal bleeding, hepatic encephalopathy, or jaundice — hormonal imbalance typically worsens, and gynaecomastia may become more pronounced.

For men who achieve significant improvement in liver function — for example, following successful treatment of hepatitis C with direct-acting antivirals, or sustained alcohol abstinence — there is some evidence that hormonal profiles can partially normalise, and gynaecomastia may stabilise or improve. However, established fibrotic gynaecomastia is unlikely to resolve spontaneously, as the glandular tissue becomes replaced by fibrous stroma over time. This underscores the importance of early recognition and treatment while the tissue remains in the active, tender phase.

Regular monitoring for men with cirrhosis and gynaecomastia should include:

• Periodic reassessment of breast tissue for any change in size, consistency, or new symptoms

• Ongoing liver function and hormonal monitoring as part of routine hepatology follow-up

• Hepatocellular carcinoma (HCC) surveillance with six-monthly liver ultrasound, with or without AFP, for appropriate at-risk patients with cirrhosis who would be candidates for treatment — in line with NICE NG50 and BSG/BASL guidance. Surveillance is not recommended universally for all patients with cirrhosis; eligibility should be assessed individually.

• Psychological support, as body image concerns and the broader burden of chronic liver disease can significantly affect mental wellbeing

Men living with cirrhosis and gynaecomastia should be encouraged to maintain open communication with their hepatology team, report any new breast symptoms promptly, and engage with lifestyle measures — particularly alcohol reduction or cessation — that may slow disease progression and improve overall hormonal health.

Frequently Asked Questions